Showing results (451-460 of 501) with videos related to

Sort By:
Pageof 51
Blood|June 14, 2022
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Blood|August 1, 2022
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphomaSwetha Kambhampati Thiruvengadam, Monica Saumoy, Yecheskel Schneider, et al.
Leukemia & Lymphoma|April 10, 2020
Repurposing leflunomide for relapsed/refractory multiple myeloma: a phase 1 studyMichael Rosenzweig, Joycelynne Palmer, Ni-Chun Tsai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 14, 2016
Value, Access, and Cost of Cancer Care Delivery at Academic Cancer CentersElizabeth A Nardi, Julie A Wolfson, Steven T Rosen, et al.
Science Advances|December 23, 2022
ACTR5 controls CDKN2A and tumor progression in an INO80-independent mannerXiaobao Xu, Anthony K N Chan, Mingli Li, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
American Journal of Hematology|March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell LymphomaGeoffrey Shouse, Matthew Matasar, Lu Chen, et al.
Iscience|July 12, 2024
Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLCTamara Mirzapoiazova, Liz Tseng, Bolot Mambetsariev, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 22, 2015
Elevated incidence of fractures in women with invasive breast cancerB J Edwards, W J Gradishar, M E Smith, et al.
Pageof 51